Adverse drug reactions represent a common clinical problem. They are partly induced by a large variability in drug
response, which results from the complex interplay between pharmacokinetics, pharmacodynamics and other
disease-associated factors. The reviewde scribes metabolic changes caused by polymorfism in the cytochrome P450
and gives examples of induction and inhibition of this enzyme system in relation to adverse drug interaction. From
the clinical point of view, attention should be paid especially to antidiabetics, anticoagulants and phenytoin.
Therapeutic drug monitoring and genetic-based individualization of the therapy with polymorphically metabolized
drugs with narrow therapeutic range can contribute to the decreased incidence of adverse drug reactions.
adverse drug reactions, drug interactions, drug metabolism, genetic polymorfism.